– pre-commercial pilot study set to commence in 30,000-patient primary care facility in Paris –
TORONTO, ON / July 19, 2022 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that its minority-owned subsidiary, Tech2Heal SAS, has reported that it is readying the release of “Alakin”. Alakin is a SaaS-modelled comprehensive, HEALTHcare MAnagement Platform (“health.map” for short) targeted for use by healthcare providers and pharma, is natively developed in FHIR standards to guarantee high interoperability, and is fully HIPPA compliant. Alakin consists of a clinical dashboard for use by multi-disciplinary care teams that interacts with a conversational mobile app for patient use (IOS and Android). Alakin is a readily configurable, user-friendly “Swiss army knife” tool that promotes improved productivity of healthcare organizations, while providing them with the ability to create easily scaled engagement tools that link multi-disciplinary care teams with their patients – both for monitoring and vertical digital therapy purposes.
Alakin is targeted for release in August 2022, with pilot studies set to commence in hospitals and clinics located in multiple locations, for a six-month trial period.
The first of these pilot studies will be conducted at a 30,000-patient primary care facility located in Paris, France. The director of this facility sees great potential for Alakin to significantly automate and optimize the workflow involved with their overall patient care, as well as with their administration processes. They recognize that the integrative approach of the Alakin suite of tools will allow them to replace several non-interoperable softwares that they currently use, with a single, unified Alakin process, thus saving them substantial time and money.
“We at AI/ML are truly thrilled by the potential of Alakin” said Tim Daniels, Chairman of AI/ML Innovations Inc. “In addition to Tech2Heal’s plans for the platform in Europe and South America, we are also looking forward to deploying the technology in the North American marketplace through AI/ML’s subsidiary, AI Rx Inc., which owns the North American distribution rights to this exciting technology. Importantly, CPT codes already exist in the US to pay care teams for services such as Alakin.”
Fabrice Pakin, CEO and Founder of Tech2Heal added:
“There is a growing market need for personalized programs to monitor and care for patients remotely, while maintaining high-quality standards of care and patient satisfaction. Alakin results in improved patient engagement and significant time savings for the care teams, thanks to its automation and intuitiveness. Importantly, in France CPT codes are being created this year, so the platform cost of Alakin will be covered by insurer reimbursement, assisting greatly with market acceptance.”
Alakin is a SaaS-modelled comprehensive, HEALTHcare MAnagement Platform (“health.map”) targeted for use by healthcare providers and pharma, is natively developed in FHIR standards to guarantee high interoperability, and is fully HIPPA compliant. Alakin consists of a clinical dashboard for multidisciplinary care teams and a conversational mobile app for patient use (IOS and Android). Alakin is available in five languages: English, French, Spanish, German, and Portuguese. The Alakin solution facilitates connected care delivery across any clinical condition, patient profile, and treatment plan, significantly increasing patient engagement while helping to reduce adverse events.
The flexibility of Alakin enables it to easily adapt to any healthcare setting or workflow – from oncology to primary care, from diabetes to hospital-to-home transition, or even post-acute care. This flexibility is possible thanks to a powerful care pathway creator. It allows doctors to fine-tune care workflows to their needs and protocols, either creating remote care programs from scratch, or by leveraging existing protocols from ICHOM standards. These workflows are then instantly transformed into a conversational patient app, empowering patients to manage parts of their care journey themselves.
Alakin has highly configurable features and an integrated series of tools unique in the market, such as scheduling management, collaborative tools, embedded telemedicine and chat, a triage dashboard, patient records, a prescription builder, a care pathways studio, and a mobile app for patients. Alakin is available in five languages: English, French, Spanish, German, and Portuguese.
About Tech2Heal
Tech2Heal is a Paris, France based healthcare innovator specializing in digital health technologies with the objective of creating a compassionate, collaborative and patient-centered healthcare ecosystem. T2H has developed a portfolio of health-tech products and services designed to improve an individual’s mental and physical well-being by utilizing a unique blend of proprietary digital assets and remote live counselling.
Tech2Heal’s premier products include:
Qookka – clinically supported and evidence-based digital therapy for anxious and depressed patients delivered via a secure digital platform
Alakin – a bespoke, digital HEALTHcare MAnagement Platform (“health.map”) designed for healthcare providers and pharma. Assisted self-care become reality for patients and care team members alike.
For more information: https://www.tech2heal.com/
About AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (70% owned by AIML), Tech2Heal (up to 22% ownership rights, with 9.44% currently owned), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company’s stakeholders. AI/ML’s shares are traded on the Canadian Securities Exchange under the symbol “AIML”, the OTCQB Venture Market under “AIMLF”, and the Frankfurt Stock Exchange under “42FB”.
On behalf of the Board of Directors
Tim Daniels, Executive Chairman